Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 12/2008

01-12-2008 | Article

Assessing gene–treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program

Authors: P. W. Franks, K. A. Jablonski, L. M. Delahanty, J. B. McAteer, S. E. Kahn, W. C. Knowler, J. C. Florez, for the Diabetes Prevention Program Research Group

Published in: Diabetologia | Issue 12/2008

Login to get access

Abstract

Aims/hypothesis

The single nucleotide polymorphism (SNP) rs9939609 in the fat mass and obesity associated gene (FTO) and the rs7566605 SNP located 10 kb upstream of the insulin-induced gene 2 gene (INSIG2) have been proposed as risk factors for common obesity.

Methods

We tested for genotype–treatment interactions on changes in obesity-related traits in the Diabetes Prevention Program (DPP). The DPP is a randomised controlled trial of 3,548 high-risk individuals from 27 participating centres throughout the USA who were originally randomised to receive metformin, troglitazone, intensive lifestyle modification or placebo to prevent the development of type 2 diabetes. Measures of adiposity from computed tomography were available in a subsample (n = 908). This report focuses on the baseline and 1 year results.

Results

The minor A allele at FTO rs9939609 was positively associated with baseline BMI (p = 0.003), but not with baseline adiposity or the change at 1 year in any anthropometric trait. For the INSIG2 rs7566605 genotype, the minor C allele was associated with more subcutaneous adiposity (second and third lumbar vertebrae [L2/3]) at baseline (p = 0.04). During follow-up, CC homozygotes lost more weight than G allele carriers (p = 0.009). In an additive model, we observed nominally significant gene–lifestyle interactions on weight change (p = 0.02) and subcutaneous (L2/3 [p = 0.01] and L4/5 [p = 0.03]) and visceral (L2/3 [p = 0.02]) adipose areas. No statistical evidence of association with physical activity energy expenditure or energy intake was observed for either genotype.

Conclusions/interpretation

Within the DPP study population, common variants in FTO and INSIG2 are nominally associated with quantitative measures of obesity, directly and possibly by interacting with metformin or lifestyle intervention.
Trial registration: ClinicalTrials.gov NCT00004992
Funding: The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute on Aging (NIA), the National Institute of Child Health and Human Development (NICHD), the National Center on Minority Health and Health Disparities (NCMHD) and the Office of Research on Women’s Health (ORWH).
Appendix
Available only for authorised users
Literature
1.
Frayling TM, Timpson NJ, Weedon MN et al (2007) A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316:889–894CrossRefPubMed
2.
Dina C, Meyre D, Gallina S et al (2007) Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet 39:724–726CrossRefPubMed
3.
Scott LJ, Mohlke KL, Bonnycastle LL et al (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341–1345CrossRefPubMed
4.
Li H, Wu Y, Loos RJ et al (2008) Variants in the fat mass- and obesity-associated (FTO) gene are not associated with obesity in a Chinese Han population. Diabetes 57:264–268CrossRefPubMed
5.
Ohashi J, Naka I, Kimura R et al (2007) FTO polymorphisms in oceanic populations. J Hum Genet 52:1031–1035CrossRefPubMed
6.
Al-Attar SA, Pollex RL, Ban MR et al (2008) Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample. Cardiovasc Diabetol 7:5CrossRefPubMed
7.
Chu X, Erdman R, Susek M et al (2008) Association of morbid obesity with FTO and INSIG2 allelic variants. Arch Surg 143:235–240CrossRefPubMed
8.
Hotta K, Nakata Y, Matsuo T et al (2008) Variations in the FTO gene are associated with severe obesity in the Japanese. J Hum Genet 53:546–553CrossRefPubMed
9.
Marvelle AF, Lange LA, Qin L, Adair LS, Mohlke KL (2008) Association of FTO with obesity-related traits in the Cebu Longitudinal Health and Nutrition Survey (CLHNS) cohort. Diabetes 57:1987–1991CrossRefPubMed
10.
Andreasen CH, Stender-Petersen KL, Mogensen MS et al (2008) Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes 57:95–101CrossRefPubMed
11.
Herbert A, Gerry NP, McQueen MB et al (2006) A common genetic variant is associated with adult and childhood obesity. Science 312:279–283CrossRefPubMed
12.
Dina C, Meyre D, Samson C et al (2007) Comment on “A common genetic variant is associated with adult and childhood obesity”. Science 315:187CrossRefPubMed
13.
Kumar J, Sunkishala RR, Karthikeyan G, Sengupta S (2007) The common genetic variant upstream of INSIG2 gene is not associated with obesity in Indian population. Clin Genet 71:415–418CrossRefPubMed
14.
Rosskopf D, Bornhorst A, Rimmbach C et al (2007) Comment on “A common genetic variant is associated with adult and childhood obesity”. Science 315:187CrossRefPubMed
15.
Skelly T, Pinheiro AP, Lange LA, Sullivan PF (2007) Is rs7566605, a SNP near INSIG2, associated with body mass in a randomized clinical trial of antipsychotics in schizophrenia. Mol Psychiatry 12:321–322CrossRefPubMed
16.
Loos RJ, Barroso I, O’Rahilly S, Wareham NJ (2007) Comment on “A common genetic variant is associated with adult and childhood obesity”. Science 315:187CrossRefPubMed
17.
Lyon HN, Emilsson V, Hinney A et al (2007) The association of a SNP upstream of INSIG2 with body mass index is reproduced in several but not all cohorts. PLoS Genet 3:e61CrossRefPubMed
18.
The Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRef
19.
The Diabetes Prevention Program Research Group (2002) The Diabetes Prevention Program: recruitment methods and results. Control Clin Trials 23:157–171CrossRef
20.
Knowler WC, Hamman RF, Edelstein SL et al (2005) Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:1150–1156CrossRefPubMed
21.
Aaron DJ, Kriska AM, Dearwater SR, Cauley JA, Metz KF, LaPorte RE (1995) Reproducibility and validity of an epidemiologic questionnaire to assess past year physical activity in adolescents. Am J Epidemiol 142:191–201PubMed
22.
Kriska AM, Knowler WC, LaPorte RE et al (1990) Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians. Diabetes Care 13:401–411CrossRefPubMed
23.
Schulz LO, Harper IT, Smith CJ, Kriska AM, Ravussin E (1994) Energy intake and physical activity in Pima Indians: comparison with energy expenditure measured by doubly-labeled water. Obes Res 2:541–548PubMed
24.
Mayer-Davis EJ, Sparks KC, Hirst K et al (2004) Dietary intake in the diabetes prevention program cohort: baseline and 1-year post randomization. Ann Epidemiol 14:763–772CrossRefPubMed
25.
Mayer-Davis EJ, Vitolins MZ, Carmichael SL et al (1999) Validity and reproducibility of a food frequency interview in a multi-cultural epidemiology study. Ann Epidemiol 9:314–324CrossRefPubMed
26.
Fujimoto WY, Jablonski KA, Bray GA et al (2007) Body size and shape changes and the risk of diabetes in the Diabetes Prevention Program. Diabetes 56:1680–1685CrossRefPubMed
27.
Gauderman W, Morrison J (2006) Quanto 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies. Available from http://​hydra.​usc.​edu/​gxe, accessed 17 September 2008
28.
Holm S (1979) A simple sequentially rejective Bonferroni test procedure. Scand J Stat 6:5–70
29.
Goldstein GL, Daun H, Tepper BJ (2007) Influence of PROP taster status and maternal variables on energy intake and body weight of pre-adolescents. Physiol Behav 90:809–817CrossRefPubMed
30.
O’Connor TM, Yang SJ, Nicklas TA (2006) Beverage intake among preschool children and its effect on weight status. Pediatrics 118:e1010–e1018CrossRefPubMed
31.
Joosen AM, Gielen M, Vlietinck R, Westerterp KR (2005) Genetic analysis of physical activity in twins. Am J Clin Nutr 82:1253–1259PubMed
32.
Kovacs P, Ma L, Hanson RL et al (2005) Genetic variation in UCP2 (uncoupling protein-2) is associated with energy metabolism in Pima Indians. Diabetologia 48:2292–2295CrossRefPubMed
33.
Fredriksson R, Hägglund M, Olszewski PK et al (2008) The obesity gene, FTO, is of ancient origin, upregulated during food deprivation and expressed in neurons of feeding-related nuclei of the brain. Endocrinology 149:2062–2071CrossRefPubMed
34.
Gerken T, Girard CA, Tung YC et al (2007) The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science 318:1469–1472CrossRefPubMed
35.
Yabe D, Brown MS, Goldstein JL (2002) Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc Natl Acad Sci USA 99:12753–12758CrossRefPubMed
36.
Bengoechea-Alonso MT, Ericsson J (2007) SREBP in signal transduction: cholesterol metabolism and beyond. Curr Opin Cell Biol 19:215–222CrossRefPubMed
37.
Dahlman I, Arner P (2007) Obesity and polymorphisms in genes regulating human adipose tissue. Int J Obes (Lond) 31:1629–1641CrossRef
38.
Rampersaud E, Mitchell BD, Pollin TI et al (2008) Physical activity and the association of common FTO gene variants with body mass index and obesity. Arch Intern Med 168:1791–1797CrossRefPubMed
39.
Reinehr T, Hinney A, Nguyen TT, Hebebrand J (2008) Evidence of an influence of a polymorphism near the INSIG2 on weight loss during a lifestyle intervention in obese children and adolescents. Diabetes 57:623–626CrossRefPubMed
Metadata
Title
Assessing gene–treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program
Authors
P. W. Franks
K. A. Jablonski
L. M. Delahanty
J. B. McAteer
S. E. Kahn
W. C. Knowler
J. C. Florez
for the Diabetes Prevention Program Research Group
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2008
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-008-1158-x

Other articles of this Issue 12/2008

Diabetologia 12/2008 Go to the issue

Article

Presence of functional hyperpolarisation-activated cyclic nucleotide-gated channels in clonal alpha cell lines and rat islet alpha cells

Article

Insulin resistance is associated with a modest increase in inflammation in subcutaneous adipose tissue of moderately obese women

Commentary

Taking a closer look at the pancreas

Research Letter

Lack of an association between GHR exon 3 polymorphism and diabetic nephropathy in the Genetics of Kidneys in Diabetes (GoKinD) population

Article

The Danish National Diabetes Register: trends in incidence, prevalence and mortality

Article

Malic enzyme is present in mouse islets and modulates insulin secretion
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits